Prerna Arora

SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies

Markus Hoffmann, Prerna Arora, Rüdiger Groß et al. · Cell · 2021 · 1K citations · Full text

Pharmacy, Immunology, Infectious Diseases +12

Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity

Markus Hoffmann, Heike Hofmann-Winkler, Joan C. Smith et al. · EBioMedicine · 2021 · 398 citations · Full text

Life Sciences, Infectious Diseases, Medicinal Chemistry +16

SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination

Markus Hoffmann, Heike Hofmann-Winkler, Nadine Krüger et al. · Cell Reports · 2021 · 242 citations · Full text

Life Sciences, Immunology, Infectious Diseases +17

B.1.617.2 enters and fuses lung cells with increased efficiency and evades antibodies induced by infection and vaccination

Prerna Arora, Anzhalika Sidarovich, Nadine Krüger et al. · Cell Reports · 2021 · 84 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17

SARS-CoV-2 variants B.1.351 and B.1.1.248: Escape from therapeutic antibodies and antibodies induced by infection and vaccination

Markus Hoffmann, Prerna Arora, Rüdiger Groß et al. · bioRxiv (Cold Spring Harbor Laboratory) · 2021 · 64 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17